Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
North Carolina Voter Guide 2024: Who's running, how, where, when to vote in NC election
Recommended
Find a flu shot
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cybin Inc
(NY:
CYBN
)
11.41
+0.96 (+9.19%)
Official Closing Price
Updated: 8:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cybin Inc
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Psyched: Millions From Institutional Investor And Fed Funding For Research, M&As, Women Veterans And More
June 06, 2023
Major Investor Commits $30 Million To Psychedelics Funding
Via
Benzinga
May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances
June 01, 2023
Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May.
Via
Talk Markets
Major Investor Commits $30M To Psychedelics Funding
May 31, 2023
Canadian psychedelics biotech Cybin Inc. (NYSE: CYBN) entered into a common share purchase agreement with institutional investor Lincoln Park Capital Fund (LPC) for the sale of up to $30...
Via
Benzinga
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
May 31, 2023
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics...
Via
Benzinga
Novel DMT Compound For Anxiety Shows Clinical Progress: Robust Effects Within 2 Minutes
May 24, 2023
Canadian clinical-stage psychedelics company Cybin Inc. (NYSE: CYBN) announced that the first group of participants have been dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing
Via
Benzinga
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
May 15, 2023
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths...
Via
Benzinga
Trial On DMT Drug For Anxiety And Depression Ends Participant Dosing, Study Results Soon Released
May 09, 2023
Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) has completed participant dosing on the part 2 of 3 of its Phase 1 trial assessing intravenous (IV) administration of proprietary DMT drug...
Via
Benzinga
April Psychedelic Drug Stocks Recap: The Ups And Downs
April 30, 2023
Via
Talk Markets
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
April 21, 2023
Via
Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
April 20, 2023
Via
Benzinga
Cybin, Mind Medicine Among Top Psychedelic Movers Of Today
April 19, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 18, 2023
April 18, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 17, 2023
April 17, 2023
Via
Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
April 17, 2023
Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules
Via
Benzinga
ATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of Today
April 14, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 13, 2023
April 13, 2023
Via
Benzinga
EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics
April 13, 2023
The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space.
Via
Benzinga
Cybin Offers Free Online Training To Facilitate Psychedelic Therapy
April 12, 2023
Cybin Inc. (NYSE: CYBN), a clinical-stage biopharma company developing innovative psychedelic-based treatment options, is launching a free online facilitation training course.
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 12, 2023
April 12, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 11, 2023
April 11, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 10, 2023
April 10, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 7, 2023
April 07, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 6, 2023
April 06, 2023
Via
Benzinga
Compass Pathways, GH Research Among Top Psychedelic Movers Of Today
April 05, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 4, 2023
April 04, 2023
Via
Benzinga
"Multi-Bagger" Portfolio Down 13% In March; Still Up Almost 6% YTD
April 04, 2023
The
Via
Talk Markets
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
April 03, 2023
Via
Benzinga
Psychedelics For Major Depressive Disorder And Anxiety Disorders: Data Suggests Cybin's Deuterated Analogs Could Work
April 03, 2023
Cybin Inc (NYSE: CYBN) recently provided updates on its innovative treatments for Major Depressive Disorder (MDD) and Anxiety Disorders during its Investor Day.
Via
Benzinga
Largest Psychedelic Stocks -3.4% In March
April 02, 2023
The munKNEE Psychedelic Drug Stocks Index was down 3.4% in March but is still +1.2% YTD. The best news is the continuing high price targets being set by analysts.
Via
Talk Markets
Psychedelic Stock Gainers And Losers From March 31, 2023
March 31, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.